Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income from Continuing Operations (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Income from Continuing Operations for 15 consecutive years, with 10584000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 1651.91% to 10584000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 23924000.0, a 1737.48% decrease, with the full-year FY2025 number at 13530000.0, down 10.32% from a year prior.
  • Income from Continuing Operations was 10584000.0 for Q4 2025 at Aytu Biopharma, down from 1965000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 3923000.0 in Q1 2025 to a low of 53063000.0 in Q1 2022.
  • A 5-year average of 9293000.0 and a median of 6693000.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 273.05% in 2025; the steepest drop was 2273.83% in 2025.
  • Aytu Biopharma's Income from Continuing Operations stood at 11548000.0 in 2021, then skyrocketed by 42.04% to 6693000.0 in 2022, then soared by 108.95% to 599000.0 in 2023, then rose by 13.86% to 682000.0 in 2024, then plummeted by 1651.91% to 10584000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Income from Continuing Operations are 10584000.0 (Q4 2025), 1965000.0 (Q3 2025), and 19228000.0 (Q2 2025).